Photo from Umang Swami/X
May 8, 2024, 07:21
Umang Swami: Prior NHT in patients with MCRPC
Umang Swami, Assistant Professor in the Department of Oncology at Huntsman Cancer Institute, shared on X:
“Most patients (63%) diagnosed with Metastatic castration-resistant prostate cancer (mCRPC) (even in 2023) never received prior Neoadjuvant hormonal therapy (NHT). .
NHT remains the most common therapy in 1L mCRPC (even in patients treated with prior NHT).”
Source: Umang Swami/X
